AIMD

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”) today announced results for the second quarter ended June 30, 2026, and provided a business update on continued execution progress for AI Nose across semiconductor manufacturing, industrial infrastructure, robotics, and healthcare-related environments.

Eddy Tsai, Chairman, President and Chief Executive Officer, commented:

“We believe AI is increasingly expanding beyond understanding text, images, and speech toward interpreting real-world environmental information. This vision continues to guide Ainos’ commercialization strategy for AI Nose. We believe future semiconductor manufacturing, industrial infrastructure, healthcare environments, and robotics applications will increasingly require intelligent environmental awareness, and AI Nose continues to advance steadily toward that objective.”

“During the first half of 2026, we continued executing our commercialization roadmap by expanding AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and robotics environments. I believe these deployments not only support commercial applications, but also continuously expand our real-world environmental dataset, strengthen our Smell ID dataset, and enhance the learning and environmental pattern recognition capabilities of our Smell Language Model (SLM), enabling our Smell AI Platform to continue evolving.”

“Since December 2025, AI Nose has accumulated approximately 613 million industrial smell data records, primarily from semiconductor manufacturing environments. We believe these growing real-world datasets represent an important foundation for the long-term development of Smell AI. We believe every new deployment expands application opportunities while further strengthening our platform’s ability to recognize and understand diverse environmental patterns, allowing our Smell AI Platform to continuously learn and evolve through real-world experience.”

“We are encouraged by the progress of our commercialization activities. As existing deployments continue to advance, strategic collaborations expand, and additional real-world data strengthens the platform, we remain focused on executing our commercialization strategy, expanding real-world applications, and steadily advancing the long-term development of our Smell AI Platform.”

Christopher Lee, Chief Financial Officer of Ainos, added, “Our second-quarter results reflect Ainos’ continued execution of its commercialization strategy. We are focused on supporting AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and other real-world environments while advancing commercialization initiatives and expanding strategic collaborations that strengthen the Company’s long-term foundation. We continue to believe our activities will help support broader revenue generation opportunities in the second half of 2026.”

Mr. Lee continued, “We remain committed to disciplined capital allocation and financial management while supporting our core commercialization strategy, technology development, and deployment priorities. We will continue focusing on operational efficiency, strategic deployment activities, and financial discipline as we execute our long-term commercialization strategy.”

Second Quarter 2026 and Recent Operational Highlights

● Advanced deployments associated with the previously announced initial $2.1 million commercial arrangement in backend semiconductor manufacturing environments.

● Continued pilot programs in selected front-end semiconductor environments.

● Expanded AI Nose deployment and validation activities across industrial and healthcare infrastructure environments, including facility monitoring, safety, ventilation, equipment, and chemical handling applications.

● Expanded research activities involving emergency care environments and exhaled breath pattern analysis.

● Continued robotics-related pilot and deployment activities.

● Supported use-case expansion through channel and integration partnerships.

● Continued development of Smell ID datasets and smell language model capabilities using deployment and pilot data.

Ainos is focused on execution, deployment, Smell ID dataset expansion, smell language model development, and strategic commercial expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. S

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

HOUSTON,

TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (“Ainos” or the “Company”) today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications.

During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model (“SLM”) through deployment and pilot activities.

“Our first quarter progress reflects a continued transition from validation activities toward broader enterprise-level infrastructure deployment readiness,” said Eddy Tsai, Chairman, President and CEO of Ainos. “We believe the operational milestones achieved during the quarter has strengthened the foundation for future scalable commercialization of Smell AI – powered by AI Nose.”

“In addition to our progress in semiconductor environments, we are expanding AI Nose deployment into healthcare infrastructure settings, including hospital utility systems, laboratory environments, HVAC-related monitoring, MRI-related environments, and critical infrastructure safety applications. We believe this represents an important long-term application category for AI-driven environmental intelligence, by enabling continuous monitoring, anomaly awareness, and operational stability for hospital operation,” Mr. Tsai concluded.

Christopher Lee, Chief Financial Officer of Ainos, added, “During the first quarter, we strengthened our balance sheet and liquidity position through the previously announced NT$90 million (approximately US$2.8 million) financing arrangement while maintaining operating discipline as we advanced commercialization activities. Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28 million.”

“Revenue during the quarter reflected the Company’s ongoing transition toward industrial and infrastructure-focused AI Nose deployments, which remain in earlier stages of commercialization and validation. We believe our current execution priorities will help support broader revenue generation opportunities in the second half of 2026,” Mr. Lee added.

First Quarter 2026 and Recent Operational Highlights

● Continued deployment activities associated with the previously announced approximately three-year $2.1 million AI Nose commercial arrangement in backend semiconductor manufacturing environments, targeting approximately 1400 AI Nose systems

● Initiated pilot and validation activities in selected front-end semiconductor environments

● Expanded industrial commercialization initiatives through a distribution partnership supporting front-end semiconductor opportunities

● Continued robotics integration and pilot activities involving robotic and quadruped systems

● Continued development of Smell ID datasets and Smell Language Model capabilities through deployment and pilot activities

● Continued optimization of AI Nose’s near-threshold sensing and pattern-recognition capabilities through ongoing deployment and validation activities, supporting earlier identification of environmental anomalies across customer environments

The Company believes that enterprise adoption of AI-driven environmental intelligence technologies is typically driven by structured implementation roadmap with phased validation, infrastructure integration, and staged deployment. Ainos is aligning its commercialization strategy with these anticipated enterprise adoption patterns as it advances AI Nose across semiconductor, healthcare infrastructure, robotics, and industrial markets.

Ainos remains focused on execution, deployment readiness, Smell ID dataset expansion, Smell Language Model development, and strategic commercial expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.

Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI No

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Ainos Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Entering 2026

AI Nose drove 499% revenue growth in 2025, with gross margin turning positive to 82.9%

2025 partnerships now driving scaled AI Nose deployments in 2026, supported by disciplined financing

HOUSTON,

TX / ACCESS Newswire / March 30, 2026 / Ainos, Inc. (NASDAQ: AIMD)(NASDAQ: AIMDW) (“Ainos” or the “Company”) today reported financial results for the year ended December 31, 2025 and outlined commercialization momentum entering 2026.

During 2025, Ainos expanded its industrial ecosystem of AI Nose platform across semiconductor, smart factory, robotics, and industrial AI environments, establishing the foundation for deployment-driven growth. AI Nose deployments combine hardware sensing with recurring software and data monetization through Smell ID and the Smell Language Model (SLM).

“2025 marked our transition in expanding AI Nose’s commercial focus from healthcare into industrial markets. Our focus in 2025 was building the platform and partnerships required for scale,” said Eddy Tsai, Chairman and CEO of Ainos. “As we enter 2026, that groundwork is translating into operational momentum, with early AI Nose deployments underway, particularly in semiconductor environments. As deployments expand, AI Nose generates Smell ID data that continuously trains our SLM, reinforcing our long-term data advantage.”

“In 2025 we maintained a disciplined financial approach while supporting SmellTech platform’s scale. Total revenue increased approximately 499% year over year, mainly reflecting progress in our AI Nose commercialization. Gross margin improved significantly to approximately 82.9% in 2025, compared to a gross loss in 2024. Total operating expenses, excluding share-based compensation, depreciation and amortization, decreased 9% year-over-year, reflecting operational discipline as we prepare for deployment-driven growth, while reported operating expense increased about 2%,” Christopher Lee, CFO, commented.

“Subsequent to year-end, we strengthened our financial position through a New Taiwan Dollar 90 million financing (approximately USD$2,820,000), providing additional liquidity to support ongoing operations and deployment execution. This capital enhances our flexibility as we scale AI Nose commercialization while maintaining a disciplined approach to capital allocation,” Lee added.

Semiconductor Deployment Scaling Gains Momentum in 2026

In 2026, Ainos has launched early-stage deployments of AI Nose systems across semiconductor environments, including:

●~200 systems for deployment in front-end wafer fabrication facilities targeted for 1Q 2026 for technical validation, supporting potential commercial integration.

●~1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing environments, targeted for completion in Q2 2026, with deposits received, and a roadmap contemplated to scale to up to 20,000 systems, subject to validation and contractual conversion.

These deployments aim to support system integration and real-world data generation in demanding semiconductor environments, serve as a foundation for scaled commercial rollout and revenue activation over time.

“We believe scent intelligence represents a new perception layer for artificial intelligence in the physical world, enabling machines to interpret environmental signals that previously could not be digitized,” Mr. Tsai concluded.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.

Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.

About Ainos, Inc.

Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of “AI” and “Nose,” is redefining machine percep